Abstract and Introduction
Mitigating drug-associated patient risk is a significant concern not only for healthcare providers but also the Food and Drug Administration (FDA). This is apparent not only by the increasing numbers of strategic drug safety programs but also by their ever increasing complexity. As the area of risk mitigation continues to grow, it is important to understand how healthcare has arrived at its current state.
Pediatr Pharm. 2011;17(2) © 2011
Children's Medical Center, University of Virginia
Cite this: Pediatric Medications and the Development of REMS - Medscape - Feb 01, 2011.